在主要投资者购买精密医药公司时,尽管财政损失很大,但Tempus AI的股票猛涨。 Tempus AI's stock soars as major investors buy into the precision medicine company, despite financial losses.

Tempus AI是一家在保健方面使用AI进行精密医学的公司,其持有的股票在主要投资者中有所增加,Bartlett & CO.将其股份翻了一番,达到800股,Sumitomo Mitsui Trust Group购买了1,016,384股。 Tempus AI, a company using AI for precision medicine in healthcare, saw its stock holdings increase by major investors, with Bartlett & CO. doubling its shares to 800, and Sumitomo Mitsui Trust Group buying 1,016,384 shares. 尽管净差值和股本回报为负值,但Tempus AI的收入增长75.4%,达到2.5574亿美元,使分析师的期望落空。 Despite a negative net margin and return on equity, Tempus AI's revenue rose 75.4% to $255.74 million, beating analyst expectations. 该公司的市场上限为115.2亿美元。 The company's market cap stands at $11.52 billion.